Estimating the impact of rituximab on bcl-2-associated resistance to CHOP in elderly patients with diffuse large B-cell lymphoma

被引：0
作者：
Mounier, Nicolas [1 ]
Briere, Josette [1 ]
Gisselbrecht, Christian [1 ]
Reyes, Felix [2 ]
Gaulard, Philippe [3 ]
Coiffier, Bertrand [4 ]
机构：
[1] Hop St Louis, AP HP, INSERM, Serv Oncohematol,U728, Paris, France
[2] Hop Henri Mondor, AP HP, Serv Hematol, Creteil, France
[3] Hop Henri Mondor, AP HP, EA2348, Dept Pathol, Creteil, France
[4] Ctr Hosp Lyon Sud, Serv Hematol, Pierre Benite, France
来源：
HAEMATOLOGICA | 2006年 / 91卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Rituximab plus CHOP (R-CHOP) has been proven to increase overall survival in aggressive bcl-2-positive lymphoma patients. Using competing risk analysis, we studied the long-term impact of this treatment in patients from a GELA trial: R-CHOP prevented from progression or relapse in both bcl-2-positive and bcl-2-negative patients without increasing the risk of death in complete remission.
引用
收藏
页码：715 / 716
页数：2
相关论文
共 8 条
  • [1] Alas S, 2001, CLIN CANCER RES, V7, P709
  • [2] CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
    Coiffier, B
    Lepage, E
    Brière, J
    Herbrecht, R
    Tilly, H
    Bouabdallah, R
    Morel, P
    Van den Neste, E
    Salles, G
    Gaulard, P
    Reyes, F
    Gisselbrecht, C
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (04) : 235 - 242
  • [3] Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma:: A study by the groupe d'Etude des lymphomes de l'adulte
    Feugier, P
    Van Hoof, A
    Sebban, C
    Solal-Celigny, P
    Bouabdallah, R
    Fermé, C
    Christian, B
    Lepage, E
    Tilly, H
    Morschhauser, F
    Gaulard, P
    Salles, G
    Bosly, A
    Gisselbrecht, C
    Reyes, F
    Coiffier, B
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (18) : 4117 - 4126
  • [4] Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20m Ab) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention
    Jazirehi, AR
    Bonavida, B
    [J]. ONCOGENE, 2005, 24 (13) : 2121 - 2143
  • [5] Jazirehi AR, 2005, CANCER RES, V65, P264
  • [6] Mounier N, 2005, ANN ONCOL, V16, P55
  • [7] Rituximab plus CHOP (R-CHOP) overcomes bcl-2-associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL)
    Mounier, N
    Briere, J
    Gisselbrecht, C
    Emile, JF
    Lederlin, P
    Sebban, C
    Berger, F
    Bosly, A
    Morel, P
    Tilly, H
    Bouabdallah, R
    Reyes, F
    Gaulard, P
    Coiffier, B
    [J]. BLOOD, 2003, 101 (11) : 4279 - 4284
  • [8] Therneau TM, 2000, STAT BIOL HEALTH, DOI 10.1007/978-1-4757-3294-8_3
1